SCHEMBL16700730

SCHEMBL16700730

COC(=O)c1ccc(CN(Cc2ccccc2)Cc2ccc(C(=O)OC)cc2)cc1.CS(=O)(=O)O

nearest known ligand 0.59

Known targets — ChEMBL curated mechanism

ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 1/20 0.58
MAPT P10636 5/20 0.56
KDM4E B2RXH2 2/20 0.56
ALDH1A1 P00352 2/20 0.56
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
TSHR P16473 1/20 0.53
RAB9A P51151 3/20 0.52
NPC1 O15118 1/20 0.51
LOXL2 Q9Y4K0 1/20 0.50
MGLL Q99685 1/20 0.49
POLB P06746 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PTPN1 P18031 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15392053 0.94 MAPT (0.61) NR3C1MAPTKDM4EALDH1A1CA1
SCHEMBL10397250 0.94 MAPT (0.61) NR3C1MAPTKDM4EALDH1A1CA1
Hydrochloric Acid SCHEMBL16699846 0.92 MAPT (0.60) NR3C1MAPTKDM4EALDH1A1CA1
SCHEMBL20902751 0.89 MAPT (0.57) NR3C1MAPTKDM4EALDH1A1CA1
SCHEMBL15392120 0.87 MAPT (0.55) NR3C1MAPTKDM4EALDH1A1CA1
SCHEMBL16700016 0.86 TAS2R14 (0.58) NR3C1PTPN1
Hydrochloric Acid SCHEMBL16700722 0.84 TAS2R14 (0.56) NR3C1PTPN1
Hydrochloric Acid SCHEMBL16700720 0.84 TAS2R14 (0.56) NR3C1PTPN1
SCHEMBL20902753 0.84 ALDH1A1 (0.64) NR3C1MAPTKDM4EALDH1A1CA1
SCHEMBL15702603 0.84 L3MBTL1 (0.60) MAPTKDM4EALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2861568-B1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIV OSLO (NO) 2019-04-17 EP disclosed
US-9951033-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2018-04-24 US disclosed
US-20170158657-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2017-06-08 US disclosed
US-9556111-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2017-01-31 US disclosed
US-20150133510-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2015-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170158657-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS TNNI3, TNNT2, MYLK2 NR3C1 3366/4885MAPT 1807/4885KDM4E 1986/4885
US-20150133510-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS TNNI3, TNNT2, MYLK2 NR3C1 3213/4885MAPT 1886/4885KDM4E 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.